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Abstract 
Large bone defects remain a major clinical orthopedic challenge. It has been predicted that 
osteoarthritis will affect over 100 million adults in the United States by the year 2030.(1) Current 
treatments for repairing bone defects include the use of bone grafts (autologous and allogenic) or 
implants (polymeric or metallic). These approaches have significant limitations due to 
insufficient supply, potential disease transmission, rejection, cost and the inability to integrate 
with the surrounding host tissue.(1) 
The engineering of bone and cartilage tissue offers new therapeutic strategies to treat bone 
defects. Several scaffold-based approaches have been used in the past. However, this thesis 
presents a novel microsphere-based scaffold approach, sintered using subcritical carbon dioxide 
for osteogenic and chondrogenic tissue regeneration.  
As a next step in the fabrication of three-dimensional tissue engineered scaffolds, this 
thesis primarily focused on subcritical carbon dioxide sintering for forming scaffolds, 
performance of these scaffolds in culture for 6 weeks, and evaluation of two different polymers 
in osteogenic and chondrogenic differentiation.  
In this investigation, both temperature and pressure (along with time) were necessary to 
control during the CO2 sintering of PCL (higher temperature and pressure conditions with longer 
exposure time), as opposed to PLGA, which was sintered at ambient temperature and pressure 
conditions (for 1 hour exposure). The results obtained showed the feasibility of using these 
constructs for bone and cartilage tissue regeneration. Biochemical analysis, gene expression and 
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histological staining were used to analyze the data. The mechanical integrity of the constructs 
was evaluated at the beginning and end of the culture period. The onset of PLGA degradation for 
the CO2 sintered microspheres in this study appeared at 1.5 weeks which affected 
chondrogenesis. With osteogenesis, the Osteogenic PLGA group showed greater calcium content 
value over the Osteogenic PCL group while PCL retained its shape, size and mechanical 
integrity and had twice as many cells per construct at 6 weeks.  
In conclusion, this thesis lays a foundation to explore numerous applications using 
subcritical carbon dioxide sintering for tissue engineering applications.  
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Chapter 1 Introduction 
 
The overall objective of this thesis was to characterize a novel microsphere-based scaffold 
sintered using dense phase subcritical carbon dioxide for osteogenic (bone) and chondrogenic 
(cartilage) tissue regeneration. To achieve this objective, dense phase carbon dioxide sintering of 
two polymer microspheres poly(lactide-co-glycolide) (PLGA) or poly(caprolactone) (PCL), was 
carried out to produce shape-specific scaffolds that would enable cell attachment and 
proliferation. The primary challenge of this thesis was to identify appropriate sintering 
conditions for PCL. The next step was to evaluate the in vitro performance of these two 
polymers for differentiation into osteogenic tissue and evaluate the performance of PLGA for 
differentiation into chondrogenic tissue and then have a detailed look at the bioactivity and tissue 
growth. Rat bone marrow mesenchymal stromal cells (rBMSCs) were used to evaluate the 
differentiation into osteogenic and chondrogenic tissues. Differentiation of rBMSCs was 
characterized according to biochemical content and histological staining. Gene expression was 
quantified via RT-PCR. Additionally, the mechanical integrity of the constructs was tested.  
To achieve the overall objective, two specific aims were designed: (1) to fabricate a novel 
dense phase CO2 sintered PLGA and PCL microsphere based scaffold, and (2) evaluate in vitro 
performance of PLGA and PCL scaffolds in osteogenic and chondrogenic differentiation of rat 
bone marrow mesenchymal stromal cells (rBMSCs).  
The organization of the remaining chapters is as follows: 
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Chapter 2 serves to provide background information in which the literature pertinent to 
subsequent chapters is reviewed. Also provided in Chapter 2 is a discussion of applications of 
carbon dioxide (CO2) technology in the field of tissue engineering, various scaffold fabrication 
methods making use of CO2 technology, encapsulation of growth factors and mammalian cells 
using CO2 and various factors effecting the porosity in scaffolds prepared using CO2 technology 
and its effect on tissue growth. 
After the background information is established in Chapter 2, Chapters 3 addresses the 
experiments performed to satisfy the aforementioned specific aims. The deliverables included 
osteogenic and chondrogenic gene expression, biochemical output, tissue synthesis, and 
mechanical properties of constructs cultured with rat bone marrow mesenchymal stromal cells 
(rBMSCs).  
Chapter 4 contains the conclusion. Findings from all experiments are summarized in a 
global context and future research directions are discussed.  
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Chapter 2  The Future of Carbon Dioxide for Polymer Processing in 
Tissue Engineering 
 
2.1 Abstract 
The use of CO2 for scaffold fabrication in tissue engineering was popularized in the mid-
1990s as a tool for foaming polymer scaffolds, but had fallen out of favor to some extent due to 
challenges with pore interconnectivity.  However, the issue of pore interconnectivity has been 
addressed by virtue of merging pores by creating extremely high porosities.  In addition to CO2 
foaming, several groups have leveraged CO2 as a swelling agent to impregnate scaffolds with 
drugs and other bioactive additives, and for encapsulation of plasmids within scaffolds for gene 
delivery.  Moreover, in contrast to CO2 foaming, which typically relies on supercritical CO2 at 
very high pressures, CO2 at much lower pressures has also been used to sinter polymeric 
microspheres together in the presence of cells to create cell-seeded scaffolds in a single step.  
CO2 has a number of advantages for polymer processing in tissue engineering, including its ease 
of use, low cost, and the opportunity to circumvent the use of organic solvents.  With its 
numerous advantages, and the continuing diversification of its uses, a resurgence in the 
application of CO2 in tissue engineering is being witnessed. 
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2.2 Introduction:  
Carbon dioxide has found enormous uses in virtually all fields of science and research over 
the past several decades. Its use as a supercritical fluid, along with its plasticizing and solvent 
properties have enabled it to be used in a wide variety of tissue engineering and regenerative 
medicine applications.(2) In the field of tissue engineering, scaffolds provide a platform for cell 
attachment and proliferation, which can be achieved with the 3D biomaterial having a high 
porosity and high pore interconnectivity.(3) The presence of pores in the scaffold enables 
nutrient and oxygen transport, waste removal, and helps in the growth and proliferation of the 
cells. The majority of current processing techniques for scaffold fabrication use organic solvents 
and/or high temperatures.(3) Carbon dioxide technology provides an alternative to these methods 
with many applications described in the literature.(4)  
Colton and Suh (5) in 1987 reported one of the first use of CO2 and N2 to produce foams of 
polystyrene. The first mention of CO2 foams for tissue engineering scaffolds can be found in a 
1991 patent,(6) a technique that was first brought to the tissue engineering literature by Mooney 
et al. (7) in 1996, who made porous disks of poly (D, L-lactic-co-glycolic acid) by exposure to 
CO2 for prolonged periods of time. While porosities up to 93% were obtained, there was only 
partial interconnectivity between the pores. They also observed the presence of a non-porous 
skin layer, which turned out to be a major challenge to overcome for other groups that followed 
as well.  
The use of supercritical CO2 for generating porous polymeric foams has generated 
significant interest over the years. Several advancements have been made in the tissue 
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engineering field since its first use by Mooney et al.(7) Most of the techniques utilizing 
supercritical fluid technology in pharmaceutical and drug delivery applications have been 
reviewed eloquently and thoroughly by Howdle and Shakesheff.(8) Hence, this review will not 
attempt to address previously reviewed methods, and will focus instead on recent developments 
in tissue engineering applications. The processing conditions developed for improving porosity 
and pore interconnectivity in these three-dimensional constructs will also be discussed. The 
impetus for this review is that with the rapid growth in the number of advanced biomaterials and 
fabrication methods for scaffolds in tissue engineering, the field has largely moved away from 
CO2 in fabrication methods, but there are a number of advantages and opportunities with CO2 of 
which many investigators are not aware. CO2 processing is relatively straightforward and 
affordable to incorporate in a laboratory, and we encourage both industry and academia to take 
another look at what CO2 may add to their particular application. 
 
2.3 Properties of Carbon Dioxide 
A supercritical fluid is a dense phase fluid whose pressure and temperature are above its 
critical point. At the critical point of a substance, a single phase occurs that has liquid-like 
density and gas-like viscosity and compressibility.(9) It is important to note that above the 
critical temperature, compression yields a continuous increase in fluid density without 
condensation to a liquid state. These properties can be easily tuned by changes in pressure and 
temperature. Supercritical fluid and dense-phase gas (near-critical) technology is an area of 
intense fundamental and applied research, especially as an environmentally-benign solvent 
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alternative. Carbon dioxide is the most often used substance, in part because it has a low critical 
temperature and pressure (Tc=31.1 ˚C and Pc=73.8 bar), as seen in Figure 1, which makes it 
suitable for processing thermo-sensitive compounds. Furthermore, it has the additional 
advantages of being inexpensive, non-toxic and non-flammable. The recovery of final products 
and removal of CO2 can be done easily with no residue left behind.(10)  
CO2 helps in reducing the polymer melt viscosity (11-15) by decreasing the glass transition 
temperature (Tg) or melting temperature (Tm) due to its high solubility in polymers.(16) The 
molecular structure and morphology of polymers greatly influence CO2 solubility and 
diffusivity.(8) The carbonyl or ether groups in the backbone or on side chains of a polymer 
interact with CO2 and help with the dissolution of CO2 within the polymer. Polymers that have 
ether groups in their backbone structure such as poly(ethylene glycol) (PEG) have been shown to 
have stronger interactions with CO2 than polyesters, which have ester functional groups in their 
main chains. This has been attributed to weak Lewis acid-base interactions between them.(17) 
Steric hindrance can also influence solubility of CO2 in the polymer. In the case of poly(lactic 
acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA), both polymers have the same chemical 
structure in their main chains, but the solubility of CO2 is higher in PLA than in PLGA. PLGA 
co-polymers that have high lactic acid content also have fewer methyl groups, which enable 
them to have less hindrance during their interaction with CO2. The accessible free volume caused 
by methyl pendant groups also improves solubility. Therefore, with increasing glycolic acid 
content in PLGA copolymers, the solubility of CO2 decreases.(18) Also, for highly crystalline 
polymers like PLA (98:2, 20% crystallinity), PGA, PEG and PCL, CO2 has a relatively low 
solubility and it cannot easily diffuse at temperatures below their melting points. Amorphous 
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poly(DL-lactic acid) (PDLLA) and  PLGA allow CO2 to diffuse more easily due to the presence 
of a large free volume within their structures.(19) 
All of these properties have widely enabled CO2 to be used in the field of tissue 
engineering for various applications such as in the production of polymer scaffolds and 
composites, encapsulation and release of bioactive compounds, and encapsulation of mammalian 
cells.(8)  
 
2.4 Preparation of 3D Scaffolds in Tissue Engineering 
Porous three-dimensional scaffolds used in tissue engineering, help with cell attachment, 
differentiation and proliferation to regenerate a given tissue of interest.(20-22) Particularly for 
musculoskeletal tissues, the biodegradable constructs must have adequate mechanical integrity to 
support the cells and the load bearing activities of the tissue. They may also benefit from having 
appropriate physico-chemical properties to release a bioactive compound that would help guide 
the cells in integrating with the surrounding tissue.(23) To date, several methods have been 
reported in the literature for the preparation of 3D scaffolds, some of which include processes 
such as solvent casting with particulate leaching,(24) compression molding,(25) freeze 
drying,(26) heat sintering,(27, 28) injection molding,(29) layer-by-layer printing (30) or sintering 
(31) and electrospinning.(32) Each of these methods has its own advantages, but these methods 
typically make use of large amounts of organic solvents and/or exposure to elevated 
temperatures. Supercritical and dense-phase fluid technologies provide an attractive alternative 
to these traditional methods of scaffold fabrication. In this section, we discuss the strategies that 
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have been applied for creating three-dimensional porous polymer-based scaffolds and their 
applications from a tissue engineering perspective. Among several scaffold design parameters, a 
select few like pore size, porosity, and processing conditions are of high interest.   
2.4.1 Gas foaming 
Gas foaming is one of the most commonly used techniques making use of supercritical 
fluid technology for the fabrication of 3D scaffolds for tissue engineering. It was first described 
by de Ponti et al. in a 1991 patent where gas foaming was used for making scaffolds with closed 
pore structures from biodegradable poly(α-hydroxyacids) like PLLA, PDLLA, PGA and PLGA 
(Figure 2).(33) In this technique, the polymer is saturated with CO2, which at high pressures 
causes it to plasticize by reducing the glass transition temperature. This reduction in Tg of the 
polymer is achieved as a result of the intermolecular interactions between CO2 and the polymer. 
Greater Tg depression is observed in polymers that have stronger interactions. Following 
saturation of the polymer with CO2, rapid depressurization causes thermodynamic instability and 
results in the formation of nucleated gas cells that give rise to pores within the scaffold. This 
technique is mainly applicable for amorphous and semi-crystalline polymers that have a higher 
affinity for CO2 when compared to crystalline polymers.(10) Mooney et al.(7) popularized this 
process by making porous poly(D, L-lactic-co-glycolic acid) disks by exposure to CO2 for 3 days 
followed by rapid depressurization, which resulted in gas nucleation and formation of pores up to 
97%. However, this process also formed a non-porous skin layer over the entire surface of the 
polymer matrix, which is not suitable for cell adhesion.(7) To overcome this issue, Mooney and 
his co-workers (34) introduced salt (NaCl) particles to the polymer solution prior to gas foaming. 
Leaching of this porogen following fabrication of the polymer foam created an interconnected 
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open pore network. The degree of porosity and interconnectivity was regulated by altering the 
salt/polymer ratio and the salt particle size. They found that the polymer disks containing a large 
percentage (95%) of large NaCl particles did not have an external, nonporous skin over the 
scaffold surface.(34) Several improvements to the conventional gas foaming technique have been 
made over the last few years, enabling it to be used for various applications. Barry et al.(35) used 
the gas foaming method to create poly(ethyl methacrylate)/tetrahydrofurfuryl methacrylate 
(PEMA/THFMA) foams that were found to have about 87% porosity with nearly 57% open 
pores. These foams supported bovine chondrocyte proliferation by displaying increased 
glycosaminoglycan synthesis and retention of rounded cell morphology.   
Salerno et al.(36) combined gas foaming with microparticulate templating to achieve open 
pore biodegradable foams made of PCL with a controlled porous architecture. Composites of 
PCL were combined with micrometric NaCl particles in concentrations ranging from 70/30 to 
20/80 wt% at 70 ºC for 3 hrs at a pressure of 65 bar. It was observed that porosity, pore size and 
pore interconnectivity was controlled by optimizing the processing parameters. Spatial gradients 
of pore size and porosity were achieved within the same scaffold by using a microparticle 
concentration gradient of NaCl. Gualandi et al.(37) prepared polymeric foams of ω-
pentadecalactone (PDL) and ε-caprolactone (CL) (poly(PDL-CL)) using supercritical CO2 
foaming. They observed that foaming was possible at a temperature greater than the melting 
temperature of the co-polymer. The pore diameter and porosity were found to be dependent on 
the cooling rate. A cooling rate of 0.23 ºC/min resulted in a pore diameter of 225 µm with 70% 
porosity. Variations in pore size and interconnectivity were achieved by altering the rate of 
depressurization. Further details about the processing conditions have been listed in Table 1. 
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 Mathieu et al.(38) applied supercritical CO2 gas foaming technology to produce 
composite cellular structures having a heterogeneous architecture of pores in PLA foams 
containing hydroxyapatite (HA). They observed that addition of HA resulted in more 
heterogeneous foams than with β-tricalcium phosphate (β-TCP). Ceramic particles of HA and β-
TCP were distributed in the pore walls of the composite foams, thereby providing an efficient 
reinforcement of the matrix. These foams had an average pore size from 200 to 400 µm with 
porosities between 78% and 92%. Tsivintzelis et al.(39) found that crystalline polymers such as 
PCL can undergo supercritical CO2 foaming with the addition of small amounts of organic 
solvents such as ethanol. Addition of ethanol resulted in more uniform cell structures in the 
scaffolds than those prepared using CO2 alone, and also resulted in larger pore formation. 
However, all of the samples had a dense unfoamed skin usually apparent with the gas foaming 
technique.  
Gas foaming can produce open-cell, interconnected pores in a solvent-free process under 
the right conditions. However, the greater degree of porosity can have an effect on the 
mechanical integrity of the construct. White et al.(40) addressed this issue of optimizing porosity 
and mechanical strength. They formed foams made of different molecular weights of poly(DL-
lactic acid) (PDLLA) (57, 25 and 15 kDa) and varied the depressurization rate. During 
depressurization, super-saturation of CO2 occurred within the polymer, which led to nucleated 
bubble formation. It was observed that the rapid depressurization rate produced scaffolds with 
homogeneous pore distributions with closed pores. A decrease in depressurization rates resulted 
in wider pore distributions in the scaffolds with larger, interconnected pores. Compressive testing 
of these constructs showed that the higher MW PDLLA (52 kDa) showed elastomeric properties 
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(a linear elastic region, a collapse plateau region and a densification region), while the lower 
MW PDLLA (25 and 15 kDa) was more brittle in nature. The 52 kDa PDLLA showed potential for 
bone tissue engineering applications. Further details about improvements in processing 
conditions have been described briefly in Table 1. 
Gas foaming is one of the most commonly used techniques for making scaffolds using 
CO2. With gas foaming, a variety of conditions and parameters have been investigated with 
different materials, and common concerns being pore interconnectivity and presence of a skin 
layer, which have been addressed with approaches such as salt leaching and use of high pressures 
with slow venting times. 
2.4.2 Phase inversion 
In the phase inversion method, a polymer solution is cast onto an inert support that is then 
immersed into a bath containing non-solvent for the polymer. Contact between the solvent and 
non-solvent results in a phase separation. Carbon dioxide is the most commonly used 
supercritical fluid that is being used as a non-solvent. Using CO2 also avoids a drying step in the 
end, thereby resulting in a dry product free of all residual solvents. By tuning the process 
conditions such as pressure and temperature, the final structure of the product can be modified as 
needed.(4, 10) The phase inversion method using CO2 as a non-solvent has been used 
successfully for the preparation of different polymeric scaffolds (Table 1).  
Tsivintzelis et al.(41) used the phase inversion method to prepare PLLA foams. They 
observed that pore size decreased with pressure variation from 100-230 bar. Lesser initial 
polymer concentration led to the formation of larger pores. Reverchon et al.(42) also observed 
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that pore diameter decreased (from 15 to 7 µm) with increasing pressure (from 150 to 250 bar) 
for Poly(methyl methacrylate) (PMMA) foams. On the other hand, pore size increased from 8 to 
12 µm on increasing the temperature from 35 to 65 ºC.  
Duarte et al.(43) formed polymer matrices from starch and poly(L-lactic acid) (SPLA) by 
the phase inversion method. The resultant scaffolds had a porosity of 66% with macropores of 
200 µm in diameter and micropores of 20-50 µm in diameter. These constructs had a 90% 
swelling and a weight loss of 25% after 21 days in culture. They later applied this method to 
form chitosan foams (44) with 29% porosity and an average pore size of 62 µm. Chitosan foams 
were found to be suitable for tissue engineering of bone and cartilage due to their 
physicochemical and biocompatibility.   
Using supercritical fluid as a non-solvent during phase inversion helps in obtaining 
scaffolds that do not have any residual organic solvents. This approach has been used to form 
scaffolds from different polymeric materials and has found several applications. 
2.4.3 Supercritical fluid emulsion templating 
With the method of supercritical fluid emulsion templating, concentrated oil-in-water 
emulsions can be phase separated to create porous scaffolds. A variety of porous hydrophilic 
scaffolds can be prepared using this technique. The final porous product can be recovered by 
removing the internal phase, which is the emulsion. This technique has been extended to 
supercritical CO2-in-water emulsions as well. Butler et al.(45) used this method to stabilize the 
C/W emulsions of acryl-amide polymers by using perfluoropolyether (PFPE) surfactants and 
poly(vinyl alcohol). Following polymerization, venting of CO2 resulted in the formation of 
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interconnected pores within the polymer scaffold. They found that increasing the volume fraction 
of CO2 internal phase increased porosity. It was also observed that by increasing the 
concentration of the surfactant, greater interconnectivity within the open pores could be 
achieved.(8) This method has been scarcely studied and there is potential for others to use this 
method if they want to obtain porous hydrophilic scaffolds.  
2.4.4 Electrospinning 
Electrospinning is an intriguing method that has been used for the production of polymeric 
fibers from biomaterials and composites.(46, 47) Here, an electric field is utilized to eject a 
charged polymer stream from a needle, which then results in the formation of micro-scale fibers 
under the influence of tangential stresses and bending instabilities.(46, 48) The diameter of the 
viscoelastic jet can be reduced to produce micron and nano-sized fibers by using the electrostatic 
repulsions between the surface charges.(49) Electrospinning has been used for a variety of 
applications in tissue engineering,(48) some of which include using electrospun scaffolds for 
cartilage replacement,(50-52) bone grafts,(53, 54) cardiac grafts.(55) They can also be used for 
seeding stem cells, (56, 57) and endothelial cells (58)  to form a three-dimensional cellular 
network.  
Supercritical CO2 can be used as a swelling agent for polymers and can help impregnate the 
scaffolds with desirable additives such as drugs and bioactive compounds. Ayodeji et al.(48) 
embedded electrospun PCL with carboxytetramethylrhodamine using near critical CO2 at a 
pressure of 3.44 MPa for a period of 2.5 hrs. They found that the individual fibers remained 
intact and showed a distinct non-woven fibrous network at a low temperature of 10 ˚C, but at a 
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higher temperature of 40 ˚C, the microstructure of the fibers began to change. They also 
observed a significant distribution of carboxytetramethylrhodamine throughout the surface of the 
PCL. Encapsulation of a bioactive molecule using supercritical CO2 helps protect 
conformationally sensitive molecules from the shear forces present during the electrospinning 
process.(48) 
Levit et al.(46) used supercritical CO2 to produce poly(D,L-lactic acid) (PLA) electrospun 
fibers by using only electrostatic forces without the use of a liquid solvent. They found this new 
“supercritical fluid assisted electrospinning (SAES)” technique useful for producing large and 
small diameter fibers. 
In 2010, Liu and colleagues (47) combined the traditional electrospinning process with a 
precipitation with a compressed fluid anti-solvent (PCA) method to produce micron and 
submicron sized polymeric fibers that had either a hollow or open-cell morphology. Supercritical 
CO2 was used as the compressed fluid. Using this technique, they found that it was possible to 
obtain different fiber morphologies by simply adjusting the CO2 pressure and that high 
temperature and pressures in excess of 100 bar were not needed. They also suggested using this 
technique to encapsulate live cells to produce celloidosome fibers.(47)    
CO2 offers the advantage of obtaining different diameter fibers with open pore structures 
without using a liquid solvent. It also helps in encapsulating live cells, heat-sensitive compounds 
within the electronspun fibers.  
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2.4.5 Hydrogel foaming using CO2 
Hydrogels are highly hydrated polymeric materials that consist of hydrophilic polymer 
chains. The cross-links between the polymer chains formed by various chemical bonds and 
physical interactions contribute to the structural integrity of the hydrogels.(59) Several studies 
have been reported in the literature that use high pressure CO2 for the foaming of polymers to 
form hydrogels.  
Tsioptsias et al.(60) investigated the extent and mechanism of supercritical CO2 sorption by 
chitin hydrogels and the production of pores within these hydrogels. Chitin gels were prepared 
by dissolving chitin in a dimethylacetamide (DMA) and LiCl mixture followed by extensive 
washing in distilled water. Crosslinking within the gel was achieved by exposure to 
glutaraldehyde vapor at room temperature. They found that CO2 sorption by the gel was due to 
its dissolution in the water of the hydrogel. Foaming of the hydrogel was observed during the 
depressurization, but it immediately shrunk on exposure to air. They found that freeze-drying the 
sample immediately after depressurization helped to retain the initial porous structure formed 
during the foaming process. However, a dense outer skin was present on the surface of the 
porous hydrogels.(60) 
In 2010, Tsioptsias and others (61) proposed a mechanism for this hydrogel foaming 
technique. On depressurization, they proposed that there was heterogeneous nucleation at the 
polymer-water interface as well as homogeneous nucleation in the water phase, leading to the 
growth of pores. Following depressurization, temporary stabilization was achieved by cooling. 
Freeze-drying led to complete stabilization of the structure. In comparison, during polymer 
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foaming, there was only homogeneous nucleation in the polymer phase, which caused pore 
growth. Stabilization of the produced structure was achieved by vitrification.(61) 
Annabi et al. (62) investigated the effect of supercritical CO2 foaming on elastin-based 
hydrogels. Increasing the CO2 pressure from 30 to 150 bar caused about a 60% increase in the 
hydrogel foaming ratio. It also accelerated the crosslinking time and facilitated coacervation 
leading to enormous changes in the macro and microstructures of the pores formed within the 
sample. Increasing pressure was also found to reduce the wall thickness and size of the pores. It 
induced channels within the structure of the elastin hydrogels that promoted fibroblast 
penetration and proliferation.(62)  
CO2 has been mainly used in hydrogels for the formation of pores within the scaffolds and 
for hydrogel foaming. Using CO2 provides control over the microstructure and size of the pores 
and also helps in accelerating the crosslinking time of the hydrogels. 
 
2.5 Incorporation of Growth Factors and Mammalian Cells  
As discussed in the previous section, there are many methods utilizing supercritical fluid 
technology to prepare 3D scaffolds. While these scaffolds provide some degree of mechanical 
integrity and are biocompatible on implantation, they alone may not be sufficient to promote cell 
adhesion, proliferation and differentiation into the desired tissue. They often require the presence 
of cell signaling molecules and other bioactive compounds. Research has been carried out to 
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encapsulate drug delivery molecules, bioactive signals and cells, and genes to promote cellular 
infiltration and differentiation using CO2.  
Hile et al.(63) were among the first to incorporate growth factors into polymeric foams 
using supercritical CO2. They made porous poly(D, L-lactide-co-glycolide) containing basic 
fibroblast growth factor (bFGF) to promote angiogenesis. A homogenous water-in-solvent 
emulsion was prepared with the protein in the aqueous phase and the polymer in the organic 
phase. Saturating the emulsion with supercritical CO2 followed by depressurization led to the 
formation of porous scaffolds encapsulated with the protein. The release rate of active bFGF 
from these porous scaffolds was not as high as that from salt leached scaffolds and there was 
greater solvent residue remaining. In a similar manner, drug delivery molecules can be 
encapsulated within a porous scaffold and used for cell culture.(64) 
Duarte et al.(65) utilized a supercritical fluid impregnation method to prepare a chitosan 
scaffold containing dexamethasone. Loading of the bioactive compound was found to be most 
successful at a pressure of 8.0 MPa and a temperature of 35 ˚C, and increasing the pressure and 
temperature resulted in lower encapsulation efficiency. The release profile of dexamethasone 
was found to be sustainable.(65)  
Kanczler et al.(66) encapsulated vascular endothelial growth factor (VEGF) in PLA 
scaffolds by supercritical foaming, and seeded them with human bone marrow stromal cells. 
They found that the combination of temporally delivering VEGF from scaffolds seeded with 
hBMSCs resulted in enhanced bone regeneration of a mouse femur segmental defect.  
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Alternatively, microparticles and nanoparticles can also be used as carriers for bioactive 
compounds. Santo et al. (67) demonstrated the utility of this technique in impregnating PDLLA 
with chitosan/chondroitin sulfate nanoparticles. The scaffolds were fabricated by supercritical 
fluid foaming at 200 bar and 35 ˚C. Homogeneous distribution of the nanoparticles was observed 
throughout the 3D scaffold. It was also noted that there was swelling (water uptake) of the 
construct due to the entrapment of the nanoparticles. The resultant scaffold was found to have 
adequate mechanical integrity, porosity and pore interconnectivity for supporting cells. In vitro 
studies revealed that this system could be used as a promising candidate for dual protein delivery 
systems for potential applications in tissue engineering. 
Supercritical fluid technology is also being used to explore DNA delivery in polymeric 
foams for potential applications in tissue engineering. Nie et al.(68) is one such group that made 
use of supercritical CO2 for plasmid delivery. In their study, PLGA/chitosan foams were made 
by combining the techniques of spray drying with supercritical CO2. PLGA microspheres 
encapsulated with plasmid DNA were prepared using spray drying. The microspheres were then 
combined with chitosan molecules to form foams using supercritical CO2. CO2 pressure of 120 
bar was used for a period of 2 hr after which the pressure was reduced to ambient conditions at a 
rate of 0.05 MPa/s. Sustained DNA release was observed from these scaffolds. The integrity of 
the plasmids was also found to be well maintained. While increasing the content of chitosan 
caused a decrease in the release rate of DNA, it proved to be helpful in facilitating cell adhesion 
and viability.  
Processing of mammalian cells during supercritical CO2 foaming of scaffolds was first 
tried by Ginty et al.(69) They developed a single-step supercritical CO2 technique to prepare 
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PLA scaffolds that contained a cell suspension. Various mammalian cell types such as a 
myoblastic C2C12 cell line, 3T3 fibroblasts, chondrocytes and hepatocytes were investigated for 
their viability. Upon depressurizing, a polymer sponge containing viable cells was obtained. The 
functionality of C2C12 cells was demonstrated by their osteogenic response to the bioactive 
compound bone morphogenetic protein-2. While this is a convenient one-step process, the time-
dependent survival of cells poses a major challenge. To overcome this issue of cell viability, 
Ginty et al.(70) developed a high pressure CO2 injection port to deliver mammalian cells into an 
already plasticized scaffold during the foaming process. The cells were shown to be viable and 
were able to undergo osteogenic differentiation. In addition, the cells were able to retain both 
metabolic and enzyme activity.  
 Singh et al.(71) later formed microsphere based scaffolds containing cells by using sub-
critical CO2 sintering. Poly(lactide-co-glycolide) microsphere scaffolds were sintered using a 
subcritical CO2 pressure of ~15 bar at 25 ºC for 1 hour followed by depressurization at a rate of 
~0.14-0.21 bar/sec. During subcritical CO2 sintering, the equilibration of CO2 in the polymer is 
restricted due to the short exposure time and low pressure conditions, which leads to a 
comparatively reduced plasticized state than that achieved during gas foaming. The microspheres 
retained their spherical shape during this process and the slight swelling of the microsphere 
surfaces and subsequent adhesion (and possibly reptation) led to sintering of the adjoining 
microspheres, thereby resulting in a porous matrix. They applied this technology to form porous 
scaffolds that facilitated the growth of chondrocytes for cartilage tissue engineering applications. 
Cell viability during subcritical CO2 sintering was also evaluated in this study. Human umbilical 
cord mesenchymal stromal cells (hUCMSCs) at a density of 1x106 cells were mechanically 
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mixed with microspheres and exposed to CO2 at a pressure of 30 bar for 4 min followed by 
depressurization at a rate of ~3 psi/sec. Viability tests revealed that almost the entire cell 
population survived the sintering process. 
Carbon dioxide technology can hence be used to encapsulate a variety of compounds such 
as bioactive signals, drugs, and plasmids for gene delivery. In addition, CO2 may also be used to 
incorporate cells into scaffolds as they are fabricated, performed in a single step.  
2.6 Limitations of CO2 Technology 
Three dimensional scaffolds in tissue engineering provide a matrix for cell support, 
proliferation and differentiation. The presence of pores and interconnectivity between them helps 
the cells to proliferate, helps in nutrient and oxygen supply and waste removal. Therefore, pore 
architecture plays a crucial role in cell survival and production of ECM. Large pores help in 
nutrient supply and waste removal, but results in low cell attachment and intracellular signaling, 
whereas small pores have the opposite effect.(72, 73) Lack of porosity and interconnectivity in 
the scaffolds hampers cell growth. CO2 technology offers the advantage of preparing 3D 
scaffolds without the use of harmful organic solvents, which are deleterious for cells. However, 
lack of control on pore size and pore interconnectivity and lack of mechanical integrity are some 
of the issues with some CO2 technologies, which can limit their use. In addition, the presence of 
a non-porous skin layer over CO2-foamed scaffolds is also a drawback. In this section, recent 
attempts to overcome some of the limitations of CO2 technology will be discussed.  
Tai et al.(74) identified the trends in pore growth and porosity by analyzing the effect of 
various parameters like soaking time, soaking pressure, soaking temperature, depressurization 
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rate, molecular weight and chemical composition of the polymer. They prepared a porous 
structure of PLA and PLGA by a CO2 foaming process. The scaffolds had a non-porous skin 
layer present, which was removed prior to cell seeding and drug release studies. The results 
demonstrated that pore size decreased with increasing glycolic acid content for PLGA scaffolds. 
However, increasing glycolic acid content also resulted in lower porosity, with a maximum of 
78% porosity obtained from PLGA scaffolds. Constructs made of polymers with low molecular 
weight (i.e., PLGA 85:15 with 15 kDa and PLGA 75:25 with 13 kDa) were found to be very 
fragile. A higher pressure and a longer soaking time facilitated the production of smaller pores as 
more CO2 molecules diffused through the polymer matrix, thus leading to a higher nucleation 
density. Larger pores were obtained by increasing the temperature, as this increased the rate of 
diffusion, which allowed pore growth. Rapid depressurization resulted in the formation of large 
pores while increasing the rate of depressurization allowed pore growth.  
Reverchon et al.(75) prepared a foamed PLLA scaffold that had an elevated porosity of 
above 90% with pore interconnectivity. Regarding mechanical integrity, the compressive 
modulus (Young’s modulus determined from tensile experiments) was 81 kPa. The scaffolds 
were prepared by a three step process where a polymeric gel loaded with a solid porogen (in this 
case fructose) was first formed. The next step involved drying of the gel with supercritical CO2, 
followed by washing with water to eliminate the porogen. Pore size was controlled by the size of 
the porogen added during the process. 
Addition of microparticulate silica has been attempted to improve the pore 
interconnectivity in scaffolds prepared by supercritical CO2 foaming.(2) It was found that by 
increasing the amount of silica particles in the polymer, smaller pores could be obtained that had 
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greater interconnectivity. Porosity was not affected by the presence of silica during CO2 
foaming. 
Baker et al.(76) prepared porous resorbable polymer constructs by means of supercritical 
CO2 processing that had structural and mechanical properties similar to human bone. A porous 
PDLGA construct was soaked in supercritical CO2 followed by rapid depressurization. The 
constructs were then freeze-fractured with liquid nitrogen in the vertical and perpendicular 
directions. A lower CO2 processing temperature of 35 ˚C helped form larger pores with thicker 
pore walls, while processing at 100 ˚C formed relatively smaller pores with a very low extent of 
pore interconnectivity. Using different CO2 processing pressures had a similar effect on the pore 
architecture. It was reported that all of the constructs had a dense “cortical” shell about 15-20 µm 
thick with an interconnected porous “core” with pore diameters in the range of 236-239 µm. 
Mechanical integrity and water uptake capacity was found to be dependent on the glycolic acid 
content of the polymer.  
Despite improvements in the pore architecture, use of gas foaming techniques still results 
in the formation of a non-porous skin layer. The rapid diffusion of the dissolved fluid out of the 
sample edges results in the formation of this dense, non-porous skin layer, which can be 
decreased by increasing the pressure.(77) Though the presence of this layer is not desirable for 
tissue engineering applications, it can be easily removed manually.(39) Porosity and pore size 
can be controlled using different pressures and temperatures. Higher pressure and longer soaking 
times can result in the formation of smaller pores. A longer depressurization rate can also help in 
smaller pore formation. Addition of porogens and silica has been found to improve pore 
interconnectivity.  
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2.7 Summary 
The formation of scaffolds with desirable properties for tissue engineering applications 
remains a challenge. The conventional CO2 foaming process has been developed extensively to 
prepare porous scaffolds with a high degree of porosity and pore interconnectivity from both 
natural and synthetic polymers. Process parameters such as temperature, pressure, 
depressurization rate, soaking time, venting time, and chemical properties of the polymer are 
governing factors for controlling the macro and micro-architecture of the 3D construct.  
Preparation of 3D constructs that are able to reproduce the highly complex spatial 
organization of cells and extracellular matrix as seen in complex tissues is the need of the day. 
Scaffolds that are characterized by spatial gradients of porosity and pore size, (36) thereby 
mimicking the natural tissue, offer an interesting dimension to the latest developments in the 
field.  
In conclusion, supercritical fluid technology offers an attractive alternative over 
conventional 3D scaffold fabrication techniques for formation of porous polymeric foams and 
incorporation of bioactive molecules without the use of organic solvents or high temperatures. 
The plasticizing and solvent properties of CO2 have enabled it to be used in different research 
areas. A few key findings include the use of scCO2 as a swelling agent for polymers to help 
impregnate the scaffold with desirable additives such as drugs and bioactive compounds as well 
as using CO2 as a compressed fluid to obtain different polymer morphologies at lower 
temperatures and pressures less than 100 bar. Another major finding is the use of CO2 at much 
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lower pressures to sinter together microspheres in the presence of cells. A variety of processing 
conditions for fabrication of scaffolds using CO2 have also been reviewed here. The goal of CO2 
technology moving forward will be to extend it to provide a more complex and dynamic 
environment for tissue growth and development.   
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Chapter 3 Use of Subcritical CO2 Sintering to Make Scaffolds from 
Microspheres of Different Polymeric Materials 
 
3.1 Abstract 
The aim of this study was to evaluate three-dimensional shape-specific microsphere based 
scaffolds comprising of poly(lactide-co-glycolide) (PLGA) and polycaprolactone (PCL) for bone 
and cartilage tissue engineering. Porous scaffolds composed of ~200 µm microspheres of either 
PLGA or PCL were prepared using dense phase CO2 sintering, which were seeded with rat bone 
marrow mesenchymal stromal cells (rBMSCs), and exposed to either osteogenic (PLGA, PCL) 
or chondrogenic (PLGA) conditions for 6 weeks. The PCL microsphere based scaffolds 
supported cell adhesion and proliferation of the seeded cells, as revealed by scanning electron 
microscopy. With the osteogenic conditions, the PLGA constructs produced an order of 
magnitude more calcium (13.5 times more calcium at week 6), while the PCL constructs had far 
superior mechanical and structural integrity (125 times stiffer than PLGA at week 6) along with 
double the cell content of the PLGA constructs. Chondrogenic differentiation was limited in 
PLGA constructs, perhaps as a result of a degradation rate that was too high. The current study 
represents the first long-term culture of CO2-sintered microsphere-based scaffolds, and has 
established important thermodynamic differences in sintering between the selected formulations 
of PLGA and PCL, with the former requiring adjustment of pressure only, and the latter 
requiring the adjustment of both pressure and temperature.   
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3.2 Introduction 
In recent years, microsphere-based scaffolds have found a significant number of 
applications in the field of tissue engineering.(78-82) Microspheres offer the advantages of 
control over release rate of the encapsulated drug, degradation kinetics of the polymer and ease 
of fabrication.(83) Scaffold properties can be tailored by altering the microsphere design. Further 
control over the macromechanical and degradability properties of the scaffold can be achieved 
by selecting a suitable polymeric raw material. Poly(lactic-co-glycolic acid) (PLGA) and 
polycaprolactone (PCL) are two polymers that have been extensively used for various 
applications such as in drug delivery, diagnostics and other applications of clinical and basic 
science research, including cardiovascular disease, cancer, vaccine and tissue engineering. (84) 
These polymers offer control over the degradation properties, which can be modified by altering 
one or more factors such as molecular weight, co-polymer ratio, tacticity, crystallinity, etc.(85, 
86)  
Techniques used to prepare microsphere-based scaffolds include solvent casting/ 
particulate leaching,(24) solvent/non-solvent treatment (using acetone and ethanol),(87) heat 
sintering (27, 28) and an anti-solvent sintering technique using ethanol.(88) Each of these 
methods has its own advantages, but they mostly make use of large amounts of organic solvents 
and/or exposure to elevated temperatures, which limit their use. CO2 technology provides an 
attractive alternative to these traditional methods of scaffold fabrication. CO2 has been widely 
used since it has a low critical temperature (Tc=31.1 ˚C and Pc=73.8 bar), which makes it suitable 
for processing thermo-sensitive compounds. It has the advantages of being inexpensive, non-
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toxic and non-flammable. The recovery of final products and removal of CO2 can be done easily 
with no residue left behind.(10) 
Continuing upon the work of Singh et al. and utilizing the plasticizing properties of CO2 to 
produce scaffolds using monodisperse microspheres,(89) the goal of the present study was to 
induce osteogenesis and chondrogenesis over a 6 week culture period using rat bone marrow 
mesenchymal stromal cells (rBMSCs). An additional purpose of this study was to examine the 
sintering of microspheres of either PLGA or PCL, with the former requiring adjustment of 
pressure only, and the latter requiring the adjustment of both pressure and temperature. 
 
3.3 Materials and Methods 
3.3.1 Scaffolding materials 
Poly(D,L-lactic acid-co-glycolic acid) copolymer (PLGA) having a lactide:glycolide 
content of 50:50, molecular weight (MW) ~42,000-44,000 Da, and  an intrinsic viscosity of 0.37 
dL/g was purchased from Lakeshore Biomaterials (Birmingham, AL). Poly(ε-caprolactone) 
(PCL) having an intrinsic viscosity of 1-1.3 dL/g and MW of ~110,000-125,000 Da was 
purchased from LACTEL Absorbable Polymers (Birmingham, AL). Poly(vinyl alcohol) (PVA; 
88% hydrolyzed, MW~25,000 Da) was purchased from Polysciences, Inc. (Warrington, PA). 
Dichloromethane (DCM; HPLC grade) was obtained from Fisher Scientific (Pittsburgh, PA).  
28 
 
3.3.2 Preparation of microspheres 
Uniform PLGA and PCL microspheres were prepared by a method that was introduced by 
previous members in the group. (88, 90, 91) Briefly, using acoustic excitation produced by an 
ultrasonic transducer, regular jet instabilities were created in the polymer stream that produced 
uniform polymer droplets. An annular carrier non-solvent stream (0.5% w/v PVA) in double 
distilled water, ddH2O) surrounding the droplets, was produced using a nozzle coaxial to the 
needle. The polymer/carrier streams flowed into a beaker containing the non-solvent. The 
polymer droplets were stirred for 3-4 hours to allow solvent evaporation, which were then 
filtered and rinsed with distilled water to remove residual PVA, and stored at -20 ºC. The 
particles were then lyophilized for 48 hrs and stored. A 10% polymer solution for PCL and 20% 
polymer solution for PLGA were used to prepare the microspheres.  
3.3.3 Scaffold fabrication 
 Scaffolds were fabricated by exposure to sub-critical levels of CO2 in a custom-designed 
stainless steel vessel having a pressure safety rating of 60 bar. Specific amounts of microspheres 
(80 mg of PLGA or 60 mg of PCL microspheres) were loaded into a Teflon mold and exposed to 
CO2. Based on parameters selected following preliminary studies, PLGA microspheres were 
exposed to a CO2 absolute pressure of 364 psi (~25 bar) at room temperature for a period of 1 
hour followed by depressurization at the rate of 0.101 psi/s for 1 hour. Various combinations of 
temperature, pressure and exposure time were investigated for PCL scaffold fabrication 
(Appendix D ).  Following this, exposure to an absolute pressure of 690 psi (47.6 bar) at 45 ºC 
for a period of 4 hours followed by depressurization at a rate of ~0.2 psi/s for 1 hour was found 
to be optimum for PCL scaffold fabrication. The target was to obtain a comparable degree of 
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sintering between PLGA and PCL as evidenced by porosity, SEM imaging and integrity over 1 
week in PBS at 37ºC. Scaffolds of the dimensions 7.5 ± 0.2 mm diameter and 2.5 ± 0.2 mm 
height were obtained by this method. Scaffolds were stored at room temperature until further use. 
The porosities of the cylindrical scaffolds were calculated as:  
  Porosity = (1-ρapp /ρ) x 100%                     (1.0) 
Where ρapp is the apparent density of the scaffold, given by ρapp = 4 m/πd
2h, ρ is the density 
of the stock PLGA or PCL, m is mass of the cylindrical scaffolds, h is thickness and d is the 
diameter.  
3.3.4 Scanning electron microscopy (SEM) 
 Scaffolds in culture were fixed in glutaraldehyde followed by dehydration in ethanol. 
Critical point drying of both PLGA and PCL scaffolds was done by dissolving in 
hexamethyldisilazane (HMDS) for 30 min followed by coating with a gold/palladium target. The 
imaging was performed using a Leo 1550 field emission scanning electron microscope at an 
accelerating voltage of 5 kV under a high vacuum.  
3.3.5 Cell harvest 
Rat bone marrow stem cells (rBMSCs) were obtained from the femurs of fifteen young 
male Sprague-Dawley rats (176-200 g, SASCO) following a University of Kansas approved 
IACUC protocol (175-08). Briefly, all rats were euthanized by exposure to CO2 for 5 minutes 
followed by removal of the leg bones.  The femur was then separated from the tibia and all 
excess muscle was removed. The marrow cavity was then flushed out of the femur using a 
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syringe filled with 1% Antibiotic-Antifungal/PBS solution. All cells obtained were plated for 
expansion in monolayer up to P1 and incubated at 37 ºC (NuAire, Autoflow, 5% CO2, 90% 
humidity). The culture medium for rBMSCs was composed of Alpha MEM, 1% Penicillin-
Streptomycin (both from Invitrogen Life Technologies, Carlsbad, CA), 10% fetal bovine serum 
qualified (FBS; Gemini, West Sacramento, CA) and was changed every 2-3 days. After the 
second passage (P2), the cell solution was re-suspended at the density of 1 million cells per mL 
of the freezing medium (Cell Culture Freezing Media DMSO, Fisher Scientific). The cell 
suspensions were transferred to cryotubes and stored at -80 ºC overnight in Mr. Frosty freezing 
containers (Nalgene, Rochester, NY). The cell suspensions were later transferred to a liquid 
nitrogen cryogenic storage tank at -196 ºC for future use.  
3.3.6 Description of experimental groups 
 The study groups were divided into four categories. All scaffolds were seeded with 
rBMSCs. The first group consisted of a PLGA control that was cultured in plain BMSC media in 
the absence of growth factors. Two groups were cultured in osteogenic media (described below), 
either PLGA or PCL. Finally, the last group consisted of PLGA scaffolds cultured in 
chondrogenic media (described below) with the presence of TGF-β3 in the culture media. 
3.3.7 Cell seeding 
Frozen rBMSCs were thawed and plated at a density of 40,000 cells/cm2. When the flasks 
were about 80-90% confluent, they were trypsinized and re-plated at the same density and 
expanded up to P4 in 300 cm2 flasks. The cells were then re-suspended and seeded at a density of 
10 million cells/mL of the scaffold. Scaffolds were sterilized by ethylene oxide prior to seeding. 
31 
 
After sterilization, the scaffolds were air dried in a fume hood for 1 day and placed in a 24-well 
plate. All scaffolds were evenly distributed among all groups. 55.2 µL (50% of the scaffold 
volume, which approximately corresponds to the pore volume (88)) of the cell suspension was 
placed directly on top of the scaffolds, allowing cells to penetrate into the scaffold via capillary 
action. The cells were then allowed to attach for 3 hours and the scaffolds were denoted as “week 
0” at this point of time. 1.5 mL of the respective culture media was then added to all scaffolds 
and they were cultured statically. The culture medium for the PLGA control group consisted of 
alpha MEM, 1% penicillin-streptomycin (both from Invitrogen Life Technologies, Carlsbad, 
CA) and 10% fetal bovine serum qualified (FBS; Gemini, West Sacramento, CA). Both PLGA 
and PCL osteogenic groups were cultured in medium consisting of Dulbecco’s modified Eagle 
medium (DMEM-LG; Invitrogen, Carlsbad, CA), 1% penicillin-streptomycin, 10% fetal bovine 
serum qualified, 50 µg/mL L-ascorbic acid (Sigma), 10 nM 1 α,25 dihydroxyvitamin D3 
(Biomol International, Plymouth Meeting, PA), 10 mM β-glycerophosphate (disodium salt, 
pentahydrate; Calbiochem, San Diego, CA), 0.1 µM dexamethasone and 50 ng/mL BMP-2 
(Peprotech, Inc., Rocky Hill, NJ). The PLGA chondrogenic group was cultured in medium 
composed of DMEM-high glucose (Invitrogen), 1X insulin-transferrin-selenium (ITS)-premix 
(BD Biosciences, San Jose, CA), 50 µg/mL L-ascorbic acid (Sigma), 1% penicillin-
streptomycin, 40 µg/mL L-proline, 100 µM sodium pyruvate (Fisher Scientific, Pittsburgh, PA), 
1% non-essential amino acids (NEAA) (Invitrogen) and 10 ng/mL transforming growth factor 
(TGF)-β3. TGF-β3 and BMP-2 are widely used for inducing chondrogenesis (92, 93) and 
osteogenesis,(94, 95) respectively, and hence were used in soluble form in the media. Media 
were replaced for all constructs every 48 hrs. After 3 weeks in culture, 15 mM HEPES buffer 
(Fisher Scientific) was added to all groups to control the pH.  
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3.3.8 Biochemical analyses 
 At weeks 0, 3 and 6, constructs (n=4) were analyzed for matrix production using 
biochemical assays. The constructs were digested by adding 1.2 mL of papain solution 
comprising of 125 µg/mL papain (from papaya latex, Sigma), 5 mM N-acetyl cysteine, 5 mM 
ethylenediaminetetraacetic acid (EDTA), and 100 mM potassium phosphate buffer in ddH2O (20 
mM monobasic potassium phosphate, 79 mM dibasic potassium phosphate in ddH2O). The 
constructs were placed in microcentrifuge tubes containing papain solution and left overnight at 
60 ºC. After digestion, the scaffolds were centrifuged at 10,000 rpm for 5 minutes to form a 
pellet of the polymer and other impurities and later stored at -20 ºC for biochemical analysis. The 
supernatant was later used to analyze DNA, and hydroxyproline (HYP) content, and for the 
chondrogenic and control groups, also glycosaminoglycan (GAG) content.     
The DNA content was analyzed using a PicoGreen kit (Molecular Probes, Eugene, OR) 
according to the manufacturer’s protocol. GAG content, which is an important component of 
connective tissues such as cartilage, was determined using a dimethylmethylene blue (DMMB) 
assay kit according to the manufacturer’s instructions (Biocolor, Newtownabbey, Northern 
Ireland). Briefly, about 1 mL of DMMB was added to 100 µL of each sample and allowed to 
bind for 30 minutes. The pellet was then collected via centrifugation and resuspended and read at 
656 nm. Hydroxyproline content, a major component of collagen, was determined using a 
modified HYP assay method.(96) Briefly, 400 µL of each sample was hydrolyzed with an equal 
volume of 4N NaOH at 121 ºC for 30 min. It was then neutralized with an equal volume of 4N 
HCl and titrated to a pH of 6.5-7. Approximately 500 µL of this solution was combined with an 
equal volume of chloramine-T solution buffer comprising of 50 g/L citric acid, 120 g/L sodium 
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acetate trihydrate, 34 g/L sodium hydroxide and 12.5 g/L acetic acid. The resultant solution was 
later combined with 500 µL of 1.17 mM p-dimethylaminobenzaldehyde in perchloric acid and 
read at 550 nm. A conversion factor of 11.5 can be used to convert the hydroxyproline mass to 
collagen content based on our previous studies. 
To determine alkaline phosphatase (ALP) activity and calcium content for the osteogenic 
and control groups, constructs (n=4) were homogenized in 1 mL of 0.05% Triton X-100 (Sigma) 
and stored at -20 ºC. Elevated ALP activity is an indicator of active bone formation as ALP is a 
byproduct of osteoblast activity. To analyze the ALP activity, the plates were lysed twice using 
the freeze-thaw cycles. About 20 µL of the lysate was then combined with 100 µL 2-amino-2-
methyl-1-propanol (AMP) buffer and incubated at 37 ºC for 75 min. The wells turned yellow, 
following which the reaction was stopped by the addition of 100 µL of 0.5M NaOH and 
subsequently read at 405 nm. The total ALP activity was expressed as a measure of liberated p-
nitrophenol concentration/µg protein/min, as described elsewhere.(97) The protein content was 
determined by combining 20 µL of the lysate with 40 µL BioRad reagent and subsequent reading 
at 600 nm.  
Calcium content was determined by using QuantiChromTM Calcium Assay Kit (DICA-500; 
QuantiChrom) according to the manufacturer’s instructions.  
3.3.9 Quantitative polymerase chain reaction 
Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed on scaffolds as 
a measure of gene expression. To perform RT-PCR, scaffolds (n=4) at weeks 0, 1, 2, 3 and 6 
were homogenized in 1 mL of Trizol reagent (Invitrogen) and preserved at -80 ºC. RNA was 
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later isolated according to the manufacturer’s instructions and converted to cDNA using a 
TaqMan High Capacity kit (Applied Biosystems, Foster City, CA) in a BioRad ThermoCycler. 
Assay IDs of TaqMan gene expression assays were Hs00164004_m1 for COL1A1, 
Hs00173720_m1 for IBSP, Hs00231692_m1 for RUNX2, Hs00202971_m1 for ACAN, 
Hs00165814_m1 for SOX9, Hs00156568_m1 for COL2A1 and Hs99999905_m1 for 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and this reaction was carried out in an 
Applied Biosystems 7500 Fast Real-time PCR System. A 2-∆∆Ct method was used to evaluate the 
relative level of each target gene.(98) For quantification purposes, the control PLGA group at 
week 0 was designated as the calibrator group, with GAPDH expression as an endogenous 
control.   
3.3.10 Histological staining 
 Samples from week 3 and week 6 (n=3) for all groups except Osteogenic PCL were 
removed from the culture and placed in Optimal Cutting Temperature (OCT, Tissue-Tek) 
embedding medium and allowed to equilibrate overnight at 37 ºC. The samples were then 
preserved at -20 ºC for future use. 16 µm thick sections were cut perpendicular to the construct 
axis using a cryostat (Micron Hm-550 OMP, Vista, CA) and collected on SuperFrost Plus slides 
(Fisher Scientific). The slides were fixed in chilled acetone prior to staining. 
 Methyl methacrylate (MMA) embedding was carried out for the Osteogenic PCL 
constructs (n=3) from week 3 and 6, which was done because frozen sectioning of these 
constructs was not possible. The cryo-sectioning embedding medium was softer than the 
constructs. They were fixed in 10% neutral buffered formalin for 1 day followed by dehydration 
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in graded alcohol for 6 hours. The samples were then immersed in infiltrate solution in a glass 
vial and left for 1 day at room temperature on a shaker. The infiltrate solution comprised of 8.4 
mL methyl methacrylate, 1.4 mL dibutylphthalate, 100 µL polyethylene glycol 400 (PEG 400) 
and 70 mg benzoyl peroxide (BPO) for each specimen. Following infiltration, the samples were 
placed in individual glass vials consisting of 10 mL of embedding solution and placed at 4 ºC for 
3 days. The embedding solution (n=1) was made up of 8.4 mL methyl methacrylate, 1.4 mL of 
dibutylphthalate, 100 µL polyethylene glycol 400 (PEG 400), 40 mg benzoyl peroxide and 33 µL 
of N,N-dimethyl-ptoludine (DMT). Sectioning of the plastic embedded scaffolds was carried out 
using a microtome (Thermo Scientific Microm HM355S microtome). About 10 µm thick 
sections were obtained and placed on gelatin coated slides. They were covered with a precut 
piece of polyethylene film to make the sections flat and placed in a 42-45 ºC incubator for one 
day. Prior to staining, the polyethylene film was removed and all of the slides were deplasticized 
in 2-methoxyethylacetate followed by acetone and deionized water.  
Safranin-O/Fast Green staining for GAGs, Alizarin Red for calcium depositions and von 
Kossa staining for calcium phosphate deposition and Hematoxylin and Eosin staining for cell 
nuclei and ECM was carried out on all samples. Finally, the slides were dehydrated in graded 
alcohol (95% and 100% ethanol, twice each) and cleared in xylene prior to mounting.  
Immunohistochemistry (n=3) was also performed for types I and II of collagen in a 
BioGenex i6000 autostainer (BioGenex, San Ramon, CA). Slides were hydrated with PBS for 5 
min. Endogenous peroxidase activity was inhibited using 1% hydrogen peroxide in methanol for 
30 min. Each section was then blocked with a 3% horse serum solution for 30 min followed by 
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incubation with a primary antibody for 1 hour. Mouse monoclonal IgG anti-collagen I (1:1500 
dilution; Accurate Chemical and Scientific, Westbury, NY) and mouse monoclonal IgG anti-
collagen II (1:1000 dilution; Chondrex, Redmond, WA) were the primary antibodies used in this 
study.  Following primary antibody incubation, the sections were incubated with a streptavidin-
linked horse anti-mouse IgG secondary antibody (Vector Laboratories, Burlingame, CA) for 30 
min. The sections were then incubated with an avidin-biotinylated enzyme complex (ABC 
complex; Vector Laboratories) for 30 min, and later with VIP substrate (purple color) (Vector 
Laboratories) for 10 min. Negative controls with the primary antibody omitted were also run.  
3.3.11 Mechanical testing 
Mechanical characterization of the constructs (n=5) was carried out using a uniaxial testing 
apparatus (Instron Model 5848, Canton, MA, 50 N load cell) under unconfined compression 
using a custom-built bath-platen apparatus (99). Cylindrical scaffolds prepared by CO2 sintering 
were tested under simulated physiological conditions (i.e., phosphate buffered saline (PBS) 
comprised of 0.138 M sodium chloride, 0.0027 M potassium chloride at 37 ºC). At week 0, cell-
seeded scaffolds of PCL and one group of PLGA were tested (7.8 ± 0.2 mm diameter, 1.7 ± 0.7 
mm height for PCL constructs; 8.3 ± 0.3 mm diameter, 1.8 ± 0.5 mm height for PLGA 
constructs). It was assumed that there would be no detectable differences in the mechanical 
properties of the three PLGA groups at week 0 given that those scaffolds were all identical. At 
week 6, all four groups were tested. The dimensions of the constructs at week 6 were 13.7 ± 1.4 
mm diameter, 1.1 ± 0.5 mm height for the Control PLGA constructs.  The Chondrogenic PLGA 
group were 13.6 ± 1.2 mm in diameter and 2.5 ± 0.8 mm in height. The osteogenic groups had a 
diameter of 11.8 ± 1.7 mm and a height of 1.9 ± 0.6 mm height for the PLGA group and a 
37 
 
diameter of 7.5 ± 0.2 mm and a height of 1.9 ± 0.4 mm for the PCL group. Compressive moduli 
of elasticity were obtained from the linear regions of the stress-strain curves. A continuous 
deformation rate of 5 mm/min was used during the compression testing. The stress was defined 
as the ratio of the load to the initial cross-sectional area, and the strain was defined as the ratio of 
the change in length to the original length.     
3.3.12 Statistical analyses 
Statistical analyses were performed using a single factor analysis of variance with a 
Tukey’s post hoc test (ANOVA) in Origin 6.0 software. All quantitative results (numerical 
values and representative diagrams) were expressed as the average ± standard deviation.  
 
3.4 Results 
3.4.1 Microspheres and scaffold fabrication 
PLGA and PCL microspheres having uniform diameter were prepared using Precision 
Particle Fabrication method.(90) The microspheres displayed high monodispersity and had a 
nominal diameter of ~200 µm.   
Cylindrical scaffolds containing two types of polymers, PLGA and PCL, were produced 
using subcritical CO2 as previously described. Morphological assessment of the scaffolds using 
scanning electron microscopy (SEM) revealed that there were slight distortions on the surfaces 
of the microspheres, but the spherical shape was largely retained as seen in Figure 3. SEM 
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images of the Chondrogenic PLGA group were not available as they were unable to withstand 
SEM processing. The microsphere matrices were also found to be porous. Scaffolds with a final 
diameter of 7.5 ± 0.2 mm and a height of 2.5 ± 0.2 mm were formed resulting in a scaffold 
volume of 110.4 µL. The porosity was calculated according to equation (1) and was found to be 
44.6 ± 4.1% for PCL scaffolds and 43.2 ± 0.2% for PLGA scaffolds (no statistically significant 
difference). SEM imaging after 6 weeks showed that PCL microspheres retained their spherical 
shape while PLGA microspheres completely degraded (Figure 3). 
3.4.2 DNA content 
The overall DNA content for all constructs decreased over the period of 6 weeks (p < 0.05) 
as seen in Figure 4. There was a statistically significant decrease in DNA content for each group 
at weeks 3 and 6 compared to their week 0 values. The three PLGA groups decreased by 70% at 
week 6 (p < 0.005) compared to their week 0 values while the Osteogenic PCL group decreased 
by 38% at the end of week 6 (p ≤ 0.01). However, the DNA content in the Osteogenic PCL 
group was found to be significantly higher than the Control PLGA group at weeks 3 and 6. There 
was 2.0 times higher DNA contents in the Osteogenic PCL group compared to the Control 
PLGA group at weeks 3 (p < 0.005) and 6 (p ≤ 0.01), respectively. The average DNA contents in 
the remaining three groups were found to be similar to each other at week 6.  
3.4.3 Glycosaminoglycan content  
GAG analysis was carried out on only two groups: Control PLGA and Chondrogenic 
PLGA. Statistically significant differences in the GAG content were not observed in either group 
over time (Figure 5).   
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3.4.4 Hydroxyproline content 
The hydroxyproline (HYP) data for all groups is shown in Figure 6. Statistically significant 
differences in the absolute HYP were not observed for any group during the 6 weeks. 
All of the three PLGA groups showed a significant increase in HYP/DNA content at weeks 
3 and 6 compared to the week 0 Control PLGA group (p < 0.01). No significant changes were 
observed in the Osteogenic PCL group throughout the 6 weeks. However, its value was observed 
to be 1.9 times lower than the Control PLGA group at week 3 (p < 0.01) and week 6 (p < 0.05). 
By 3 weeks, the Control PLGA and the Chondrogenic PLGA constructs made 3.0 times (p < 
0.005) and 4.2 times (p < 0.001), respectively, more HYP/DNA than their previous time point. 
The Osteogenic PLGA constructs showed no significant increase in HYP/DNA content at week 
3 compared to its week 0 value. However, at 6 weeks, the Osteogenic PLGA group had 2.3 times 
higher HYP/DNA content (p ≤ 0.001) than the week 0 Control PLGA group. Significant 
differences between the two osteogenic groups were not observed. 
3.4.5 Calcium content 
Calcium content for all constructs showed no statistically significant changes until week 2 
(Figure 7). At week 2, the Osteogenic PLGA group increased 22 times over its week 0 value (p ≤ 
0.02), the Control PLGA group increased by a factor of 5.1 (p < 0.001) while Osteogenic PCL 
group did not change significantly. The Osteogenic PLGA group had 6.2 times more calcium 
than the control group at week 6 (p < 0.001) and 10.0 times more than the Osteogenic PCL group 
(p < 0.001) at week 6.  
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Normalized data showed a similar trend with increases in calcium content from week 2 
onward. The Osteogenic PLGA and Control PLGA groups had significantly higher calcium 
contents at week 2 (35.9 times higher, p ≤ 0.02 for Osteogenic PLGA; 12.6 times higher, p < 
0.001 for Control PLGA) and week 3 (44.6 times higher, p < 0.001 for Osteogenic PLGA; 21.3 
times higher, p ≤ 0.05 for Control PLGA) compared to the their week 0 value. The Osteogenic 
PCL group did not show any significant increase in calcium content over its week 0 value (p > 
0.05). Calcium content in the Osteogenic PLGA group was found to be significantly higher when 
compared to the PCL group at weeks 2 (10.2 times higher, p ≤ 0.03), 3 (12 times higher, p < 
0.001) and 6 (13.5 times higher, p < 0.001). 
3.4.6 Alkaline phosphatase activity 
The Osteogenic PCL and PLGA groups had significantly lower ALP activity than the 
Control PLGA group at weeks 0 and 1 (Figure 8). The Control PLGA group showed a 64% 
decrease in its ALP activity (p ≤ 0.002) at the end of 6 weeks when compared to its week 0 
value, and the Osteogenic PLGA group also experienced a decrease in ALP activity  from week 
0 to week 6, being 82.6% lower (p < 0.005). However, the ALP activity of the Osteogenic PCL 
constructs increased by 2.0 times at the end of 6 weeks relative to its week 0 value (p ≤ 0.03). 
The ALP activity of the Osteogenic PCL group was found to be 2.3 times higher than the 
Osteogenic PLGA group at week 3 (p < 0.001) and 5.8 times higher at week 6 (p < 0.001).  
3.4.7 Gene expression 
All treatment groups showed a slight increase in COL1A1 expression over the period of 6 
weeks (Figure 9). There was observed to be a 21.3 fold increase in COL1A1 expression for the 
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Osteogenic PCL group at week 3 over its week 1 value (p < 0.005). Significant changes in 
expression over the previous time points were not observed for the Osteogenic PLGA group. 
However, its expression was significantly lower than the Control PLGA group at week 1 (6.1 
times lower, p ≤ 0.02) and week 3 (5.04 times lower, p ≤ 0.02). A significant difference was 
observed between the two osteogenic groups at weeks 3 and 6 (p < 0.05). COL1A1 expression 
was found to be 7.0 times higher in the Osteogenic PCL group than in the Osteogenic PLGA 
group at week 6 (p < 0.05).  
  Statistically significant changes in COL2A2 expression were observed in all groups over 
the period of 6 weeks (Figure 10). The chondrogenic PLGA group exhibited an 11 fold increase 
in expression at week 1 over its week 0 value (p < 0.01). Statistically significant changes in 
expression were also seen between the two osteogenic groups at week 1. The Osteogenic PCL 
group had 123 times higher expression (p ≤ 0.001) than the Osteogenic PLGA at week 1.  
 Runx2 expression increased 10.1 times at week 3 over its week 1 value for the 
Osteogenic PCL group, and decreased later at week 6 (p < 0.001) while the Osteogenic PLGA 
group showed a 3.7 times increase at week 6 over its week 1 value (p < 0.001). Runx2 
expression of the Osteogenic PLGA group at week 3 could not be detected. Significant 
differences in Runx2 expression were not observed between the two osteogenic groups (Figure 
11).  
 No significant changes were observed in aggrecan expression throughout the culture 
period (Figure 12). The highest expression in all four groups was observed at week 3 with values 
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decreasing later at week 6 (not statistically significant). Significant differences in expression 
between the two osteogenic groups were not observed.  
 Relative expressions of Sox-9 and BSP gene were not reported due to their low gene 
expression values.  
3.4.8 Histological staining 
Staining for cell nuclei with Hematoxylin & Eosin (H&E), Safranin-O/Fast Green for GAG 
content, Alizarin Red for calcium deposition and von Kossa for calcium phosphate was carried 
out on all groups. At 3 weeks (Figure 13), all constructs demonstrated a negligible degree of Saf-
O staining, with the Osteogenic PCL group having some staining detected near the periphery of 
the microspheres. Cell nuclei, visualized by H&E staining, were present mainly toward the 
periphery of the scaffolds. Visualization of cells was particularly difficult with the Chondrogenic 
PLGA constructs. Alizarin Red staining seemed to be present almost throughout the construct, 
with the highest concentration in the edges of the scaffolds for all groups, except for the 
Chondrogenic PLGA group. The Control PLGA and Osteogenic PLGA groups showed more 
intense staining for calcium, both staining more intensely than the Osteogenic PCL group. von 
Kossa staining was used to identify the presence of calcium phosphate deposits in the constructs. 
At week 3, the Osteogenic PLGA group showed the presence of von Kossa staining distributed 
throughout the construct. The control PLGA construct also exhibited some von Kossa staining to 
a lesser extent, and traces of von Kossa staining were seen in the Chondrogenic PLGA group. It 
was difficult to discern any von Kossa staining in the Osteogenic PCL group at week 3.  
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By 6 weeks (Figure 14), the density of cell nuclei decreased in all groups except for the 
Osteogenic PLGA group, which had a larger number of cells near the outer boundary of the 
construct. In addition, Saf-O staining was only observed in the Osteogenic PCL group while 
Alizarin Red staining was most prominent in the Control PLGA group, particularly around the 
periphery. The Osteogenic PLGA group also showed noticeable staining for Alizarin Red, 
however to a somewhat lesser extent, with slightly more intense staining around the periphery as 
well. Alizarin Red staining was observed in trace amounts in the Chondrogenic PLGA and the 
Osteogenic PCL groups. Non-uniform clusters of von Kossa staining were observed in all groups 
with the Control PLGA group being most intensely stained, followed by the Osteogenic PLGA 
group. 
 Immunohistochemistry was also carried out on all treatment groups at weeks 3 and 6 
(Figure 15). By 3 weeks, positive immunostaining was observed for type I collagen with 
relatively more staining in the Osteogenic PCL group, followed by the Control and Osteogenic 
PLGA groups, with minimal staining for the Chondrogenic PLGA group. The presence of type II 
collagen was seen mostly in the Control PLGA group and even to some extent in the Osteogenic 
PCL group. By 6 weeks, both type I and type II collagen were seen in all groups with the most 
intense staining in the control group followed by the Osteogenic groups and the least staining in 
the Chondrogenic PLGA group. 
3.4.9 Mechanical testing 
The representative stress-strain curves from unconfined compression testing for all groups 
at week 0 and week 6 have been shown in Appendix C. All the groups except week 6 Osteogenic 
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PCL group showed an initial linear region followed by a nonlinear collapse region. The 
Osteogenic PCL group at week 6 behaved differently. The compressive moduli were determined 
from the stress-strain plots using the initial linear regions which were arbitrarily chosen, before 
the onset of the nonlinear region which generally extended up to 40% strain for all the PLGA 
groups, while the week 0 Control PCL and PLGA groups were linear up to 20% strain.  For the 
week 6 PCL group, the modulus of elasticity was calculated from the initial linear region that 
extended up to only 10% strain. Same strain range starting from 0 to 40% for all PLGA groups at 
week 6 and from 0 to 20% for week 0 groups were used (n = 5). The modulus of elasticity was 
determined to be 4.25 times higher for the PLGA constructs at week 0 (193.9 ± 47.4 kPa) than 
the PCL constructs (45.6 ± 26.3 kPa) at the same time point (p < 0.001). However, after 6 weeks 
the PCL constructs (79.8 ± 6.7 kPa) were at least 125 times stiffer than the PLGA groups (p < 
0.001). The moduli of the PLGA constructs (0.3 ± 0.1 kPa) dropped drastically after 6 weeks in 
culture. They decreased by 99.6% of their week 0 values at the end of week 6 (p < 0.001). On the 
other hand, the elastic modulus for the PCL constructs actually increased by 75% from week 0 to 
week 6 (not statistically significant).  
 
3.5  Discussion 
The overall objective of this study was to investigate the use of a novel microsphere based 
scaffold formed by subcritical CO2 sintering for osteogenic and chondrogenic tissue engineering. 
Two commonly used polymeric scaffold materials PLGA and PCL were used in this study. 
Subcritical CO2 sintering (~25 bar for PLGA at 25ºC and ~47 bar for PCL at 45ºC) was used to 
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prepare scaffolds due to the high solubility of CO2 in polymers and its ability to plasticize 
polymers by lowering the glass transition temperature or melting point.(16) From the SEM 
images at week 0 and the porosity data, comparable degrees of sintering were observed in both 
PCL and PLGA constructs. Since the molecular structure and morphology of the polymers 
greatly influence CO2 solubility and diffusivity, PLGA having more accessible free volume (due 
to lesser steric hindrance) may have a greater solubility in CO2 than PCL.(8) Perhaps due in part 
to this steric hindrance with PCL, a shorter equilibration time with CO2 was needed for PLGA (1 
hour), while PCL needed a relatively longer time (4 hours) at a higher pressure and slightly 
elevated temperature of 45ºC. Due to the relatively short exposure time, plasticization of the 
entire polymer was avoided and the microspheres were only fused with each other, thereby 
retaining their spherical shape. A moderate depressurization rate was found to be desirable 
(0.101 psi s-1 for PLGA scaffolds and ~0.2 psi s-1 for PCL scaffolds) for the production of 
sintered matrices. Instantaneous depressurization was avoided because that would result in 
foaming of the prepared scaffolds. During depressurization, thermodynamic instability occurs 
within the polymer, resulting in nucleation of gas cells. These gas cells give rise to nanopores 
within the scaffold. Faster depressurization rates could be applied in the future to increase 
porosity as well as porogens like NaCl can be added to increase the porosity.(34)  
At week 6, the presence of cells and ECM was observed in PCL constructs. The slow 
degradation rate of PCL enabled the microspheres to retain their shape throughout the 6 weeks in 
culture and no acidic byproducts were released. On the other hand, PLGA has a faster 
degradation rate. Although the swelling rates, water uptake and degradation rates were not 
calculated here, it was observed that swelling and change in size occurred as early as ten days in 
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culture for the PLGA constructs. Changes in pH were also noticeable at this stage for the PLGA 
constructs, evidenced by medium color change. Hence, to prevent further damage to cells, 
HEPES buffer was added to the culture media around week 3 to maintain the pH around 7. In 
future studies, steps may be taken to maintain the culture medium near a pH of 7 at all times, 
either by buffering of the medium or by encapsulation of buffers such as sodium bicarbonate or 
calcium carbonate.(100)  
 During the culture period, a loss of cells was observed. It has been observed that the 
DNA content decreased in PGA meshes due to its rapid degradation rate.(101) It was noted that 
the degradation rate was not equal to the rate of extracellular matrix synthesis, resulting in a 
contraction of scaffolds. Since the cell number did not further decrease from week 3 onward, it 
indicates that a more stable construct may have been achieved. The cell loss might be responsible 
for the GAG loss in the Control PLGA constructs. However, the Chondrogenic PLGA constructs 
showed an increased GAG production after week 3. Net HYP content did not show any 
significant increases over the period of 6 weeks. However, the normalized data showed an 
interesting trend with increase in HYP from week 3 onward for all groups. At week 6, the 
Chondrogenic PLGA group had the highest HYP mass. In addition, the two osteogenic groups 
were not significantly different from one another with respect to the HYP content, but their level 
was less than the control. Increased calcium content was observed for the Osteogenic PLGA 
group after week 3, indicating an onset of mineralization in those constructs. In contrast, the 
Osteogenic PCL group did not show a significant increase in calcium content. It is known that 
during osteogenic differentiation of MSCs, ALP activity decreases at later times. (102) This 
early indication of osteogenic differentiation in the PLGA group may be the reason for the low 
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ALP activity. However, further investigations need to be carried out to figure out the reasons for 
the varying trend for the other groups.  
There was a drastic drop in the mechanical integrity of the scaffolds at the end of the 
culture period for PLGA scaffolds (99% decrease). This was most likely a consequence of 
microsphere degradation, leading to disappearance of the sintering-sites. The slow degradation 
rate of PCL enabled those constructs to retain their microsphere shape and mechanical integrity 
throughout the culture period, which could have important implications in vivo. 
Certain strategies may be implemented in future studies to improve the performance of 
constructs. First, selection of an adequate PLGA polymer having higher lactic acid content, 
higher molecular weight and Tg can be utilized in microsphere preparation to decrease the 
degradation rate of the polymer. Second, a bimodal distribution of microspheres can be used 
during scaffold fabrication (89) to improve the mechanical properties of the scaffold although 
this would result in lower porosity. Addition of nanocomposite materials such as calcium 
carbonate, hydroxyapatite, or tricalcium phosphate within the microspheres can also help in 
maintaining the pH changes that occur during PLGA degradation, as well as providing “raw 
materials” to the cells and regenerating tissues in vivo.  Third, faster depressurization rates can be 
explored and porogens can be added during CO2 sintering to improve porosity. Finally, cell 
attachment and viability can be improved by functionalizing the polymer with haptotactic cues 
such as Arg-Gly-Asp (RGD) or Tyr-Ile-Gly-Ser-Arg, (YIGSR) (103) or by encapsulating natural 
“raw materials” such as those noted earlier. 
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3.6 Conclusions 
The feasibility of using a novel microsphere based scaffold sintered using subcritical CO2 
for osteogenic and chondrogenic tissue engineering has been demonstrated in this thesis. This 
work builds on the previous efforts of a student in our group with CO2-sintered microsphere-
based scaffolds (89), where cell viability was demonstrated, by completing a full 6-week in vitro 
study with both osteogenesis and chondrogenesis, as well as establishing sintering parameters for 
PCL.  
In this investigation, temperature, pressure and exposure time were necessary to control for 
CO2 sintering of PCL (higher temperature and pressure conditions with longer exposure time), as 
opposed to PLGA, which was sintered at ambient temperature and pressure conditions (for 1 
hour exposure). The PLGA degradation rate for CO2 sintered microspheres in this first study 
appeared to be too high, at the expense of chondrogenesis, which may be addressed in the future 
with encapsulated buffers and/or a slower degrading PLGA. 
With osteogenesis, there were marked differences between the PLGA and PCL constructs. 
Specifically, the PLGA group produced an order of magnitude more calcium, while PCL 
retained its shape, size and mechanical integrity and had twice as many cells per construct at 6 
weeks. Although the PCL group generally had a higher ALP activity, and even a higher level of 
Runx2 gene expression at 3 weeks, by 6 weeks the PLGA constructs had a higher Runx2 
expression while the PCL group instead had a higher aggrecan expression. 
The overall conclusion here is that PLGA may be the material of choice in a CO2 sintering 
application, based on the drastically superior calcium content observed in osteogenesis and the 
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more straightforward sintering conditions (Controlling the pressure and exposure time at ambient 
temperature), but that both chondrogenesis and osteogenesis may benefit from a slower 
degradation rate and the encapsulation of growth factors, calcium-based nanoparticles, and/or 
buffers in the microspheres. 
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Chapter 4 Conclusion 
 
Previous studies related to this work have successfully tested cell viability during the CO2 
sintering process and produced cell loaded patches and scaffolds. Potential of these scaffolds for 
cartilage tissue engineering was also shown. The studies in this thesis made the first attempt in 
using bone marrow mesenchymal stromal cells from rats for engineering bone and cartilage 
tissue using subcritical CO2 sintered microsphere-based scaffolds.  
Osteogenic and chondrogenic differentiation of rBMSCs was induced in vitro by the 
addition of BMP-2 and TGF-β3 respectively in the culture media. Biochemical analysis, gene 
expression and histology staining revealed tissue growth in the constructs. In this investigation, 
both temperature and pressure (along with time) were necessary to adjust for CO2 sintering of 
PCL, as opposed to PLGA, which was sintered at ambient temperature. The PLGA degradation 
rate for CO2 sintered microspheres in this study appeared to be too high, at the expense of 
chondrogenesis, which may be addressed in the future with encapsulated buffers and/or a slower 
degrading PLGA. With osteogenesis, there were marked differences between the PLGA and PCL 
constructs. The onset of mineralization could be seen in the Osteogenic PLGA group due to its 
high calcium value while the Osteogenic PCL group showed an increase in mechanical integrity 
of the constructs after 6 weeks in culture. PCL also retained its shape, size and mechanical 
integrity and had twice as many cells per construct at 6 weeks. Although the PCL group 
generally had a higher ALP activity, and even a higher level of Runx2 gene expression at 3 
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weeks, by 6 weeks the PLGA constructs had a higher Runx2 expression while the PCL group 
instead had a higher aggrecan expression. 
The overall conclusion here is thus that PLGA may be the material of choice in a CO2 
sintering application, given the drastically superior calcium content in osteogenesis and the more 
straightforward sintering conditions (Controlling the pressure and exposure time at ambient 
temperature), but that both chondrogenesis and osteogenesis may benefit from a slower 
degrading polymer in the future.  
Future work can include loading of growth factors within the microspheres thereby 
providing a spatiotemporal control over the release rates. The present study used growth factors 
in the soluble form in the medium. Encapsulating them within the microspheres would provide 
control over its release rate.  
Improvements to the custom-made stainless steel CO2 chamber can be made to make 
scaffolds more efficiently.  The present equipment does not have an in-built temperature and 
pressure gauge hence, the parameters could not be accurately monitored.  The experimental set-
up could be modified to provide better temperature control during the sintering of PCL. A 
pressure regulator can also be added to accurately maintain the pressure inside the vessel at a 
constant value with fewer leaks. A viewing window can be added to the chamber to be able to 
monitor the sintering process visually. 
Moderate depressurization rates of 0.1psi/sec for PCL and 0.2 psi/sec for PLGA were used 
in this study. Porosities of 42% were observed in both polymeric scaffolds. Using faster rates of 
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depressurization and different sizes of microspheres can also be investigated to improve porosity. 
Porogens like NaCl particles can also be mixed along with the polymer during the CO2 sintering 
process to improve the porosity, which has been investigated to some extent by a former post-
doctoral fellow, Ju in our group. Slightly higher porosities of 52.8±6.8% (50:50 PLGA with 25 
wt% NaCl, CO2 sintering at 25 bar for 1 hr) than that achieved in this study can be obtained with 
this improvement. Also, pore interconnectivity within the scaffolds can be investigated and 
improved as it may help with better cell attachment and proliferation. This was not addressed in 
the present study.  
PLGA copolymers having a decreased degradation rate (higher lactic acid content, high 
molecular weight) can be used. The PLGA copolymer used in this study started degrading after 
10 days in culture and resulted in a loss of cells due to the release of acidic byproducts. Inclusion 
of nano materials like calcium phosphate, hydroxyapatite or bioglass can be done to improve the 
mechanical properties of the polymeric scaffold. These nanomaterials will also be useful in 
controlling the fluctuations in the pH of the culture media during the degradation process.  
More efficient cell seeding methods can be explored. Constructs can be functionalized with 
Arg-Gly-Asp (RGD) sequence to improve cell attachment. The cell seeding method used in the 
present study had a low seeding efficiency, with cell number decreasing after week 1. Only one 
cell source rBMSCs were used in the present study. In future, different cell sources like 
umbilical cord mesenchymal stromal cells (hUCMSCs) can be also investigated for their 
potential in bone and cartilage tissue engineering applications.  
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The results presented in this thesis lay a foundation to explore numerous applications using 
subcritical carbon dioxide sintering for tissue engineering applications.  
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Appendix B 
 
Figure 1: Schematic of carbon dioxide (CO2) pressure-temperature phase diagram. 
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Figure 2: Chemical structures of some common polymers. 
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Figure 3: Selected scanning electron microscopy (SEM) images of week 0 (A) and week 6 (B) 
samples. Scaffolds were fabricated using PLGA and PCL microspheres at customized processing 
conditions for sintering (CO2 exposure at 25 bar for 1 h at 25ºC followed by depressurization at a 
rate of 0.101 psi s-1 for PLGA; 45 bar for 4 hrs at 45 ºC followed by depressurization at a rate of 
0.2 psi s-1 for PCL). Comparable degrees of sintering were observed at week 0, and microsphere 
shape was better preserved in the PCL constructs by week 6. Chondrogenic PLGA scaffolds 
have not been shown as they could not withstand SEM processing. Scale bars = 100 µm unless 
shown otherwise. 
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Figure 4: DNA content for all groups. All the three PLGA groups had statistically significant 
decrease in cell number by week 6 compared to the week 0 Control group. Only Osteogenic PCL 
group had similar cell number throughout 6 weeks. It had significantly higher cell number over 
the control group at all times. Values are reported as mean ± standard deviation, n = 4. 
Statistically significant difference @ = from the week 0 value (Control PLGA) (p < 0.05), # = 
from its value at the previous time point (p < 0.05), and * = from the control (Control PLGA) at 
that time point (p < 0.05), and ! = between the two osteogenic groups at that time point (p < 
0.05). 
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Figure 5: Glycosaminoglycan (GAG) content for the chondrogenic groups. Significant changes 
in the GAG content were not observed for the Control PLGA and Chondrogenic PLGA groups. 
Values are reported as mean ± standard deviation, n = 4.  
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Figure 6: Hydroxyproline (HYP) content for all groups. (A) Statistically significant differences 
in HYP content were not observed in any group. (B) All groups had statistically significant 
increases in HYP/DNA content at week 3 and 6. The Chondrogenic PLGA constructs had 
significantly higher production relative to control at week 0 when compared to all other groups. 
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Values are reported as mean ± standard deviation, n = 4. Statistically significant difference @ = 
from the week 0 value (Control PLGA) (p < 0.05), # = from its value at the previous time point 
(p < 0.05), * = from the control (Control PLGA) at that time point (p < 0.05), and ! = between 
the two osteogenic groups at that time point (p < 0.05). 
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Figure 7: Calcium content for the osteogenic groups. (A) Most groups had statistically 
significant increases in calcium content from week 0 to week 6, but only the Osteogenic PLGA 
constructs had significantly higher production relative to the control at 6 weeks. Notably, this 
value was at least 6 times higher than any other group at the end of the culture. At 6 weeks, the 
Osteogenic PCL group showed a decrease in calcium content when compared to the Control 
group. (B) Osteogenic PLGA constructs produced more Calcium/DNA than Control and PCL 
groups at week 6. An increasing Calcium/ DNA content trend was observed for Control and 
Osteogenic PCL groups till week 3. Week 6 showed decreased values for both groups. Values 
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are reported as mean ± standard deviation, n = 4. Statistically significant difference @ = from the 
week 0 value (Control PLGA) (p < 0.05), # = from its value at the previous time point (p < 0.05), 
* = from the control (Control PLGA) at that time point (p < 0.05) and ! = between the two 
osteogenic groups at that time point (p < 0.05).  
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Figure 8: Alkaline Phosphatase activity of the osteogenic groups. Alkaline phosphatase activity 
for all constructs showed a varying trend throughout the 6 weeks. Control PLGA group showed a 
decreasing ALP content while Osteogenic PCL had an increasing ALP content at the end of 
week 6. Osteogenic PLGA constructs had an increasing ALP activity till week 3 after which they 
decreased. Values are reported as mean ± standard deviation, n = 4. Statistically significant 
difference @ = from the week 0 value (Control PLGA) (p < 0.05), # = from its value at the 
previous time point (p < 0.05), * = from the control (Control PLGA) at that time point (p < 0.05) 
and ! = between the two osteogenic groups at that time point (p < 0.05). 
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Figure 9: Relative COL1A1 expression. Statistically significant changes in COL1A1 expression 
were observed. Increased expression over week 0 value was seen in week 3 Osteogenic PCL 
constructs. Osteogenic PLGA constructs showed no significant changes over the weeks. 
Calibrator group: Week 0 Control PLGA group. Endogenous group: GAPDH. Values are 
reported as mean ± standard deviation, n= 4. Statistically significant change of expression * = 
from the control PLGA group at that time point, # = from its value at the previous time point (p < 
0.05) and ! = between the two osteogenic groups at that time point (p < 0.05).  
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Figure 10: Relative COL2A2 expression. Statistically significant increase in COL2A2 
expression at week 1 and 3 was observed for the chondrogenic PLGA group over its week 0 
value. Increase in expression was observed the control PLGA group as well at week 6 over the 
previous time point was observed only in week 6 Osteogenic groups. There was a decrease in 
COL2A2 expression in osteogenic groups towards the end of 6 weeks. Calibrator group: Week 0 
Control PLGA group. Endogenous group: GAPDH. Values are reported as mean ± standard 
deviation, n=4. Statistically significant change of expression * = from the control PLGA group at 
that time point, # = from its value at the previous time point (p< 0.05) and ! = between the two 
osteogenic groups at that time point (p < 0.05).  
. 
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Figure 11: Relative Runx2 expression. Statistically significant changes were observed in the 
Osteogenic PLGA group. Runx2 expression was found to increase in PLGA group near week 6. 
Expression increased in the Osteogenic PCL group at week 3 while control PLGA group had a 
decrease in expression at the end of week 6. Calibrator group: Week 0 Control PLGA group. 
Endogenous group: GAPDH. Values are reported as mean ± standard deviation, n=4. 
Statistically significant change of expression * = from the control PLGA group at that time point, 
# = from its value at the previous time point (p< 0.05) and ! = between the two osteogenic groups 
at that time point (p < 0.05).  
. 
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Figure 12: Relative Aggrecan expression. Relative aggrecan expression had no statistically 
significant changes during the 6 weeks except for the control PLGA group. Increased expression 
was seen in the Chondrogenic group and the two osteogenic groups. Calibrator group: Week 0 
Control PLGA group. Endogenous group: GAPDH. Values are reported as mean ± standard 
deviation, n= 4. Statistically significant change of expression * = from the control PLGA group 
at that time point, # = from its value at the previous time point (p< 0.05) and ! = between the two 
osteogenic groups at that time point (p < 0.05).  
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Figure 13: Histological staining of constructs at week 3. At week 3, Control PLGA and 
Osteogenic PLGA constructs showed calcium and calcium phosphate deposits mainly on the 
periphery of the scaffolds. GAG staining was very low with positive staining mainly in 
Osteogenic PCL constructs. Cell nuclei were seen in all constructs except Chondrogenic PLGA 
with H&E staining. Scale bars = 100 µm. 
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Figure 14: Histological staining of constructs at week 6. Histological staining of constructs at 
week 6 revealed calcium depositions in the periphery of scaffolds for Control and Osteogenic 
PLGA groups. Reduced numbers of cell nuclei were observed in all groups except Osteogenic 
PLGA. Saf-O staining did not show a lot of GAG production. Scale bars = 100 µm.  
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Figure 15: Immunohistochemical staining for types I and II collagen. By 3 weeks, positive 
immunostaining was observed for type I collagen with relatively more expression in Osteogenic 
PLGA and Control PLGA groups. Presence of type II collagen was seen mostly in Control 
PLGA group. By 6 weeks, both type I and type II collagen was seen in all groups with maximum 
staining in the control group followed by Osteogenic PLGA group. Scale bars = 100 µm.
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Figure 16: Elastic modulus (kPa) at week 0 (A) and week 6 (B). Elastic modulus at week 0 for 
both the groups PLGA and PCL were significantly different from one another. PLGA had a 
higher modulus at 193.98 ± 47.38 kPa while PCL had a modulus of 45.59 ± 26.29 kPa. Inset 
graph represents the three PLGA groups. At week 6, a statistically significant decrease in elastic 
modulus was observed for the three PLGA groups. Osteogenic PLGA group was statistically 
higher over the control at week 6. Osteogenic PCL on the other hand, increased in elastic 
modulus after 6 weeks in culture. Values are expressed as mean ± standard deviation, n = 5.  
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Statistically significant difference @ = from the week 0 Control PLGA value (p < 0.05), and ! = 
between the two osteogenic groups at that time point (p < 0.05).  
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Appendix C 
Representative Stress-Strain curves for all groups at different time points  
 
Figure 17 : Stress-Strain curve of week 0 Osteogenic PCL group from compression testing. 
Engineering stress values (kPa) are shown. Compressive modulus extracted from the initial 
linear region (up to 20% strain). 
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Figure 18: (A) Stress-Strain curve of week 6 Osteogenic PCL group from compression testing. 
Engineering stress values (kPa) are shown. (B) Compressive modulus extracted from the initial 
linear region (up to 10% strain). (C) Compressive modulus extracted from 0 to 40% strain. 
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Figure 19: Stress-Strain curve of week 0 Control PLGA group from compression testing. 
Engineering stress values (kPa) are shown. Compressive modulus extracted from the initial 
linear region (up to 20% strain). 
 
 
Figure 20: Stress-Strain curve of week 6 Control PLGA group from compression testing. 
Engineering stress values (kPa) are shown. Compressive modulus extracted from the initial 
linear region (up to 40% strain). 
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Figure 21: Stress-Strain curve of week 6 Osteogenic PLGA group from compression testing. 
Engineering stress values (kPa) are shown. Compressive modulus extracted from the initial 
linear region (up to 40% strain). 
 
 
Figure 22: Stress-Strain curve of week 6 Chondrogenic PLGA group from compression testing. 
Engineering stress values (kPa) are shown. Compressive modulus extracted from the initial 
linear region (up to 40% strain). 
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Appendix D  
Table 2: CO2 sintering parameters for PCL 
Pressure Temperature Exposure time 
Depressurization 
time 
Result 
25 bar, 37 
bar, 40 bar, 
60 bar, 200 
bar 
Vessel temp: 25 ºC 1 hr 1 hr 
Microspheres 
did not fuse at 
all. 
25 bar, 200 
bar 
Vessel temp: 25 ºC 1 hr Overnight 
Microspheres 
did not fuse at 
all. 
200 bar 
Vessel temp: 25 ºC; 
CO2  temp inside 
pump: 30 ºC, 35 ºC, 
40 ºC 
1 hr 1 hr 
Microspheres 
did not fuse at 
all. 
40 bar 
Vessel temp: 25 ºC; 
2 mL acetone added 
inside chamber. 
1 hr 1 hr 
Completely 
melted 
40 bar 
Vessel temp: 25 ºC; 
0.5 mL acetone 
added inside 
chamber. 
1 hr 1 hr 
Completely 
melted. 
25 bar 
Vessel temp: 25 ºC; 
0.5 mL acetone 
added inside 
chamber. 
1 hr 1 hr Partially melted.
No CO2 
exposure. 
Placed in a 56 ºC 
water bath. 
N/A N/A Fused partially. 
No CO2 
exposure 
Placed in a 60 ºC 
water bath. 
N/A N/A Fused partially. 
No CO2 
exposure 
Placed in a 60 ºC 
oven. 
N/A N/A 
Completely 
melted. 
40 bar 
Vessel temp: 30-35 
ºC 
1 hr 1 hr 
Microspheres 
did not fuse at 
all. 
72 bar Vessel temp: 35 ºC 1 hr 1 hr 
Microspheres 
did not fuse at 
all. 
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60 bar Vessel temp: 40 ºC 1 hr 1 hr 
Fused partially; 
scaffold 
disintegrated on 
touching. 
47 bar, 50 
bar 
Vessel temp:42 ºC 1 hr 1 hr 
Fused partially; 
scaffold 
disintegrated on 
touching. 
45 bar 45 ºC 
1 hr,  1hr 15 min, 
2 hrs, 2 hrs 30 
min 
1 hr 
Fused partially; 
scaffold 
disintegrated on 
touching. 
45 bar 45 ºC 4 hr 15 min 1 hr 
Melted 
completely. 
45 bar 45 ºC 4 hr 1 hr 30 min 
Melted 
completely. 
45 bar 45 ºC 4 hr 30 min 
Fused partially; 
scaffold 
disintegrated on 
touching. 
45 bar 45 ºC 4 hr 45 min 
Fused 
completely with 
each other. 
Construct 
disintegrated 
after 1 day in 
PBS. 
45 bar 45 ºC 4 hr 1 hr 
Microspheres 
completely 
fused with each 
other. Construct 
retained its 
integrity after 1 
week in PBS at 
37 ºC. 
 
